{
    "symbol": "CLLS",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-04 14:29:12",
    "content": " -- the net cash flow used in operating capital expenditure and leases were $81 million at Cellectis and $17 million at Calix in the first 9 months of 2022, partially offset by a $10 million capital raise at Calix, $6 million of cash received related to research tax credit prefinancing at Cellectis and $3 million cash received from milestones and licenses. The consolidated adjusted net loss attributable to shareholders of Cellectis, excluding Calix, excluding noncash stock-based compensation expenses, was $67 million or $1.48 per share in the first 9 months of 2022 compared to a loss of $66 million or $1.49 per share in 2021."
}